Dan and Corey kick off the show by arguing against the Federal Reserve potentially cutting rates this year. They point out that inflation is persistently volatile, gas prices are soaring and hurting everyday consumers, and the Fed is "pretending that everything is OK," according to Corey. Dan also brings up the fact that 2024 being an election year may have something to do with this. (0:43)
Next, Stansberry Venture Technology editor Dave Lashmet joins the conversation to discuss the biotech industry. He explains that he doesn't see biotech as a sector, and rather he looks bottom up at biotech companies to find a drug that will have a macroeconomic effect. Because only 6% of drugs that start a Phase I trial succeed, he says being selective is crucial. Dave also describes the three phases of drug testing and the importance of efficacy and safety data. (17:55)
After, Dave talks all things weight-loss drugs. He reflects on how he knew Ozempic was going to be a blockbuster drug from his boots-on-the-ground research, the incredible room for growth in this area, and the unprecedented amounts of money that biotech companies are spending on factories to develop these weight-loss drugs. (24:36)
Further, Dave discusses why the obesity epidemic has worsened over the decades and how exactly weight-loss drugs work to increase metabolism and suppress appetite. It involves something he calls the "winter switch." Plus, Dave brings up the U.S. Food and Drug Administration approving these drugs for the purpose of reducing strokes and heart attacks by nearly 20%. (32:40)
Lastly, Dave talks about the widespread economic implications behind weight-loss drugs and other areas of the market that could be impacted, such as the airline industry. However, Dave emphasizes once again that any mass changes are still years away due to supply constraints. (41:20)
AI Is Changing Everything You've Learned About Investing
Savvy Investors 'Buy Straw Hats in Winter'
Stick to Your Process, Even When It's Painful
Ignore the Mega-Bubble Mania and Prioritize Shareholder Yield
The Best Investors Treat Trading Like Blackjack
Why Biotech Is an Excellent Contrarian Play Today
'Boring' Times Ahead Could Mean Fantastic Gains
You're Only Ever a Contrarian or a Victim in Natural Resource Investing
Tactical Turning Points Are the Secret to Finding Winners
Don't Let Your Ego Drive You to Make Bad Decisions | Harley Bassman
It's Time to Upgrade Capitalism
Successful Trading is the Antithesis of Human Nature
The Easiest Way to Rank Almost 5,000 Stocks
Get Ready for Volatility warns Greg Diamond
Don't Place all Your Chips on One Outcome
The Top 10 Potential Surprises for 2024
Stansberry Investor Hour's 2023 Year in Review - Mailbag Edition
How to Avoid Losing Your Mind in the Market with Hari P. Krishnan
Why Companies Are Afraid of Being Politically Correct with Whitney Tilson
Create your
podcast in
minutes
It is Free
The Commercial Edge: Unleash the Power of People
The emPOWERed Half Hour
Aligned Money Show
Dubai Property Podcast
IBKR Podcasts
The Ramsey Show
The Clark Howard Podcast